ArticleFrontiers in pharmacology2013
Drug development for the irritable bowel syndrome: current challenges and future perspectives.
Article in Frontiers in pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects and Mechanisms of Acupuncture on Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review.Frontiers in neuroscience · 2022Pooled it
- Agomelatine improves symptom severity and quality of life in diarrhea-predominant irritable bowel syndrome: insights from a randomized controlled clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies.International journal of molecular sciences · 2025Review
- Differential roles of serotonin receptor subtypes in regulation of neurotrophin receptor expression and intestinal hypernociception.Histology and histopathology · 2024Article
- Effectiveness of Non-Pharmacological Interventions for Irritable Bowel Syndrome: A Systematic Review.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Probiotics Modulate Mouse Gut Microbiota and Influence Intestinal Immune and Serotonergic Gene Expression in a Site-Specific Fashion.Frontiers in microbiology · 2021Article
- DA-9701 (Motilitone): A Multi-Targeting Botanical Drug for the Treatment of Functional Dyspepsia.International journal of molecular sciences · 2018Review
- Alleviation of Irritable Bowel Syndrome-Like Symptoms and Control of Gut and Brain Responses with Oral Administration ofNutrients · 2018Article
- Article
- The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial.United European gastroenterology journal · 2016Article
- Distribution of 5-HT3, 5-HT4, and 5-HT7 Receptors Along the Human Colon.Journal of neurogastroenterology and motility · 2015Article
- A systems-level "misunderstanding": the plasma metabolome in Huntington's disease.Annals of clinical and translational neurology · 2015Article
- Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.British journal of pharmacology · 2014Article
- Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy.World journal of gastroenterology · 2014Review
- Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments.World journal of gastroenterology · 2014Review
- Curcuma longa L. as a therapeutic agent in intestinal motility disorders. 2: Safety profile in mouse.PloS one · 2013Article
- Novel insights which may translate into treatments for irritable bowel syndrome.Frontiers in pharmacology · 2013Article
- Depolarizing Effects of Daikenchuto on Interstitial Cells of Cajal from Mouse Small Intestine.Pharmacognosy magazineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medications are frequently used for the treatment of patients with the irritable bowel syndrome (IBS), although their actual benefit is often debated. In fact, the recent progress in our understanding of the pathophysiology of IBS, accompanied by a large number of preclinical and clinical studies of new drugs, has not been matched by a significant improvement of the armamentarium of medications available to treat IBS. The aim of this review is to outline the current challenges in drug development for IBS, taking advantage of what we have learnt through the Rome process (Rome I, Rome II, and Rome III). The key questions that will be addressed are: (a) do we still believe in the "magic bullet," i.e., a very selective drug displaying a single receptor mechanism capable of controlling IBS symptoms? (b) IBS is a "functional disorder" where complex neuroimmune and brain-gut interactions occur and minimal inflammation is often documented: do we need to target gut motility, visceral sensitivity, or minimal inflammation? (c) are there validated biomarkers (accepted by regulatory agencies) for studies of sensation and motility with experimental medications in humans? (d) do animal models have predictive and translational value? (e) in the era of personalized medicine, does pharmacogenomics applied to these medications already play a role? Finally, this review will briefly outline medications currently used or in development for IBS. It is anticipated that a more focused interaction between basic science investigators, pharmacologists, and clinicians will lead to better treatment of IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.